What is Ebglyss (Lebrikizumab)?

Ebglyss (Lebrikizumab) is a targeted IL-13 inhibitor indicated for the treatment of moderate to severe atopic dermatitis (eczema) in adults and children 12 years and older weighing at least 88 pounds (40 kg). Ebglyss helps improve dry, itchy and irritated skin by targeting eczema inflammation throughout the body. In atopic eczema, a protein called IL-13 (interleukin 13) is involved in the inflammation that causes atopic dermatitis.

The U.S. Food and Drug Administration (FDA)approvalEbglyss is based on the results of the ADvocate-1, ADvocate-2 and ADhere studies. Two studies (ADvocate 1 and 2) showed that 38% of people taking Ebgylyss achieved clear or nearly clear skin within 16 weeks, and 10% saw these results as early as four weeks; compared to 12% of the placebo group.

Ebglyss is a drug used to treat moderate to severe atopic dermatitis (eczema), which is not well controlled despite topical prescription therapies. It can be used on adults weighing at least 88 pounds (40 kilograms) and children 12 years and older. Ebglyss is an interleukin-13 antagonist that works by blocking IL-13, reducing inflammation and improving symptoms of atopic dermatitis.

Physicians will administer Ebglyss as a subcutaneous injectionEbglyss will be given as two 250 mg injections at weeks 0 and 2, followed by 250 mg injections every two weeks until adequate clinical response is achieved at week 16 or thereafter; maintenance doses will then be monthly injections (250 mg every four weeks).

The most commonEbglyss side effects are inflammation of the eyes and eyelids, including redness, swelling and itching, injection site reactions and shingles. Ebglyss can cause serious side effects, including severe allergic reactions and serious eye problems.